Eli Lilly And Co (NYSE: LLY) announced the results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities,
Merck & Co Inc (NYSE: MRK) announced topline results from two Phase 3 trials evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve